56
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Development and Validation of an Intracranial Hemorrhage Risk Score in Older Adults with Atrial Fibrillation Treated with Oral Anticoagulant

ORCID Icon, ORCID Icon, , , ORCID Icon &
Pages 267-279 | Received 02 Sep 2023, Accepted 07 Feb 2024, Published online: 20 Apr 2024
 

Abstract

Background

High risk of intracranial hemorrhage (ICH) is a leading reason for withholding anticoagulation in patients with atrial fibrillation (AF). We aimed to develop a claims-based ICH risk prediction model in older adults with AF initiating oral anticoagulation (OAC).

Methods

We used US Medicare claims data to identify new users of OAC aged ≥65 years with AF in 2010–2017. We used regularized Cox regression to select predictors of ICH. We compared our AF ICH risk score with the HAS-BLED bleed risk and Homer fall risk scores by area under the receiver operating characteristic curve (AUC) and assessed net reclassification improvement (NRI) when predicting 1-year risk of ICH.

Results

Our study cohort comprised 840,020 patients (mean [SD] age 77.5 [7.4] years and female 52.2%) split geographically into training (3963 ICH events [0.6%] in 629,804 patients) and validation (1397 ICH events [0.7%] in 210,216 patients) sets. Our AF ICH risk score, including 50 predictors, had superior AUCs of 0.653 and 0.650 in the training and validation sets than the HAS-BLED score of 0.580 and 0.567 (p<0.001) and the Homer score of 0.624 and 0.623 (p<0.001). In the validation set, our AF ICH risk score reclassified 57.8%, 42.5%, and 43.9% of low, intermediate, and high-risk patients, respectively, by HAS-BLED score (NRI: 15.3%, p<0.001). Similarly, it reclassified 0.0, 44.1, and 19.4% of low, intermediate, and high-risk patients, respectively, by the Homer score (NRI: 21.9%, p<0.001).

Conclusion

Our novel claims-based ICH risk prediction model outperformed the standard HAS-BLED score and can inform OAC prescribing decisions.

Disclosure

Daniel E. Singer: Dr. Singer reports research support from Bristol Myers Squibb, and he has consulted for Bristol Myers Squibb, Fitbit (Google), Medtronic and Pfizer, all for unrelated work. Dae Hyun Kim: Dr. Kim reports personal fees from Alosa Health and VillageMD for unrelated work. The authors report no other conflicts of interest in this work.

Additional information

Funding

This project was supported by NIH Grant RF1 AG063381 (to Dr. Lin) and R01AG062713 and K24AG073527 (to Dr. Kim).